| Name | Title | Contact Details |
|---|
Prospect Biosystems is a Newark, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
We would love to hear from you! Please private message us with questions or feedback and we will respond as quickly as possible. General guidelines for posting on our page: • Be humane: Behind the computer screen, there are real humans with real fee...
OPTI Medical Systems leverages advanced technologies to develop reliable, cost-effective point-of-care and laboratory diagnostic solutions.